ELIEM THERAPEUTICS INC (ELYM)

US28658R1068 - Common Stock

7.71  +0.05 (+0.65%)

After market: 7.41 -0.3 (-3.89%)

News Image
17 days ago - InvestorPlace

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q1 2024

Eliem Therapeutics just reported results for the first quarter of 2024.

News Image
2 months ago - Kaskela Law LLC

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

/PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders....

News Image
2 months ago - Kuehn Law, PLLC

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

News Image
2 months ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
2 months ago - Market News Video

Thursday Sector Leaders: Drugs, Shipping Stocks

News Image
2 months ago - Eliem Therapeutics, Inc.

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have...

News Image
2 months ago - InvestorPlace

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023

Eliem Therapeutics just reported results for the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ:ELYM) just reported results for the fourth quarter o...

News Image
11 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers for Friday!

News Image
11 months ago - InvestorPlace

Why Is BioSig Technologies (BSGM) Stock Up 19% Today?

BioSig Technologies (BSGM) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NVDA) Inception program.

News Image
11 months ago - InvestorPlace

Why Is Discover Financial (DFS) Stock Down 13% Today?

Discover Financial (DFS) stock is falling on Thursday after the financial services company revealed it's undergoing a regulatory review.

News Image
11 months ago - InvestorPlace

Why Is Netcapital (NCPL) Stock Down 42% Today?

Netcapital (NCPL) stock is dropping on Thursday after the fintech company announced the pricing of a public share offering.

News Image
11 months ago - InvestorPlace

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

Eliem Therapeutics (ELYM) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives.

News Image
11 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning!

News Image
11 months ago - Eliem Therapeutics, Inc.

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a...

News Image
a year ago - Eliem Therapeutics, Inc.

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed...

News Image
a year ago - Eliem Therapeutics, Inc.

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization...